共 29 条
- [16] Jenkins Peter, 2010, J Oncol Pharm Pract, V16, P251, DOI 10.1177/1078155209351304
- [19] Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC):: impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen [J]. ANNALS OF ONCOLOGY, 2006, 17 (08) : 1205 - 1212
- [20] Adjuvant docetaxel for node-positive breast cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) : 2302 - 2313